retatrutide phase 2 results 2024 2025 press release Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished eli lilly retatrutide press release

While these actions are similar to those of GLP-1 analogs like Wegovy and Zepbound, there is some evidence that, compared to GLP-1 drugs, amylin analogs are better tolerated and help preserve lean muscle mass

This opens up a whole new pathway for communication. Hayes says researchers are now looking into how much GLP-1 gets in, where exactly the drugs go, and what behaviors or functions they cause

[1] [11] This mechanism helps improve glycaemic control whilst also promoting modest weight loss as part of diabetes management

Zhang et al., 2019 and Table 1)

Each additional receptor target adds a new dimension of metabolic activity